Efficacy and Safety Profile of CPX-351 in Secondary Acute Myeloid Leukemia (sAML): A Systematic Review

被引：0
|
作者：
Ibrahim, Ahmed [1 ]
Yousaf, Muhammad Abdullah [1 ]
Ikram, Mariam [2 ]
Khalid, Huma
Anum [3 ]
Safdar, Omar A. [4 ]
Anwer, Zain [5 ]
Faraz, Fatima [1 ]
Rehman, Mohammad [1 ]
Saad, Muhammad [2 ]
机构：
[1] Rawalpindi Med Univ, Rawalpindi, Pakistan
[2] Shifa Int Hosp Ltd, Islamabad, Pakistan
[3] Faisalabad Med Univ, Faisalabad, Pakistan
[4] Univ Arizona, Tucson, AZ USA
[5] Cleveland Clin, Cleveland, OH USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-187301
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia
    Cafaro, Alessandro
    Giannini, Maria B.
    Silimbani, Paolo
    Cangini, Delia
    Masini, Carla
    Di Rora, Andrea Ghelli Luserna
    Simonetti, Giorgia
    Martinelli, Giovanni
    Cerchione, Claudio
    MINERVA MEDICA, 2020, 111 (05) : 455 - 466
  • [32] Outcomes by number of induction cycles with CPX-351 vs 7+3 chemotherapy in older adults with newly diagnosed, high-risk/secondary acute myeloid leukemia (sAML).
    Lin, Tara L.
    Medeiros, Bruno C.
    Uy, Geoffrey L.
    Newell, Laura Fugal
    Ritchie, Ellen K.
    Stuart, Robert K.
    Strickland, Stephen Anthony
    Hogge, Donna
    Solomon, Scott R.
    Stone, Richard M.
    Bixby, Dale L.
    Kolitz, Jonathan E.
    Schiller, Gary J.
    Wieduwilt, Matthew Joseph
    Ryan, Daniel H.
    Ryan, Robert J.
    Chiarella, Michael
    Louie, Arthur Chin
    Lancet, Jeffrey E.
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [33] A Two-Part Study Evaluating the Combination of Tazemetostat and CPX-351 ( Part 1) and Palbociclib with CPX-351 (Part 2) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
    Keiffer, Gina
    Calabretta, Bruno
    Mazo, Alexander
    Outschoorn, Ubaldo Martinez
    Alpdogan, Onder
    Binder, Adam F.
    Porcu, Pierluigi
    Wilde, Lindsay
    Kasner, Margaret
    BLOOD, 2023, 142
  • [34] Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality
    Ghayas C. Issa
    Hagop M. Kantarjian
    Lianchun Xiao
    Jing Ning
    Yesid Alvarado
    Gautam Borthakur
    Naval Daver
    Courtney D. DiNardo
    Elias Jabbour
    Prithviraj Bose
    Nitin Jain
    Tapan M. Kadia
    Kiran Naqvi
    Naveen Pemmaraju
    Koichi Takahashi
    Srdan Verstovsek
    Micheal Andreeff
    Steven M. Kornblau
    Zeev Estrov
    Alessandra Ferrajoli
    Guillermo Garcia-Manero
    Maro Ohanian
    William G. Wierda
    Farhad Ravandi
    Jorge E. Cortes
    Leukemia, 2020, 34 : 2914 - 2924
  • [35] CPX-351 induces remission in newly diagnosed pediatric secondary myeloid malignancies
    Hu, Yixin
    Caldwell, Kenneth J.
    Onciu, Mihaela
    Federico, Sara M.
    Salek, Marta
    Lewis, Sara
    Lei, Shaohua
    Zhang, Jinghui
    Nichols, Kim E.
    Takemoto, Clifford M.
    Triplett, Brandon M.
    Farrar, Jason E.
    Rubnitz, Jeffrey E.
    Ribeiro, Raul C.
    Wlodarski, Marcin W.
    BLOOD ADVANCES, 2022, 6 (02) : 521 - 527
  • [36] CPX-351 with Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase Ib Study
    Bataller, Alex
    Bazinet, Alexandre
    Borthakur, Gautam
    Short, Nicholas J.
    Jabbour, Elias
    Takahashi, Koichi
    Daver, Naval
    Issa, Ghayas C.
    DiNardo, Courtney D.
    Pemmaraju, Naveen
    Jain, Nitin
    Montalban-Bravo, Guillermo
    Wierda, William G.
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Kadia, Tapan M.
    BLOOD, 2023, 142
  • [37] Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality
    Issa, Ghayas C.
    Kantarjian, Hagop M.
    Xiao, Lianchun
    Ning, Jing
    Alvarado, Yesid
    Borthakur, Gautam
    Daver, Naval
    DiNardo, Courtney D.
    Jabbour, Elias
    Bose, Prithviraj
    Jain, Nitin
    Kadia, Tapan M.
    Naqvi, Kiran
    Pemmaraju, Naveen
    Takahashi, Koichi
    Verstovsek, Srdan
    Andreeff, Micheal
    Kornblau, Steven M.
    Estrov, Zeev
    Ferrajoli, Alessandra
    Garcia-Manero, Guillermo
    Ohanian, Maro
    Wierda, William G.
    Ravandi, Farhad
    Cortes, Jorge E.
    LEUKEMIA, 2020, 34 (11) : 2914 - 2924
  • [38] Real-World Outcomes with CPX-351 Induction in Adults with Newly Diagnosed Acute Myeloid Leukemia
    Bennett, Joseph G.
    Gilmore, Drake
    Male, Heather J.
    Byrd, Kenneth P.
    Lin, Tara L.
    Gonzalez-Lugo, Jesus D.
    BLOOD, 2023, 142
  • [39] Real-World Study of CPX-351 Treatment Outcomes for Acute Myeloid Leukemia (AML) in England
    Legg, Alex
    Doubleday, Pesheya
    Reich, Adam
    Lambova, Alexandrina
    Medalla, Greg
    BLOOD, 2021, 138
  • [40] Validation of AML-score in Older Adults Receiving CPX-351 Intensive Induction Chemotherapy for Treatment of Secondary Acute Myeloid Leukemia
    Schmucker, Abigail M.
    Leiby, Benjamin E.
    Wilde, Lindsay
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (03): : E206 - E212
12345